Oxford Biomedica and Institut Merieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Merieux as part of pure-play CDMO transformation

Oxford - Oxford Biomedica plc , a quality and innovation-led cell and gene therapy CDMO, and Institut Merieux SA today announce that they have entered into exclusive negotiations with respect to the...

Related Keywords

France ,United Kingdom ,French ,Oxford Biomedica ,Frank Mathias ,Sophia Bolhassan ,Institut Merieux ,Merieux Nutrisciences ,Michel Baguenault ,European Union ,Broaden The Company ,Proposed Transaction ,Chief Executive Officer ,Mpox Virus ,Increase Oxford Biomedica ,Consideration Shares ,Volume Weighted Average Price ,Deferred Equity Subscription ,Deferred Subscription Date ,Deferred Subscription Shares ,Deferred Subscription ,Equity Partners ,News Publishing ,Markets ,